Transforming Cardiometabolic Practice with GLP-1 Receptor Agonists | Dr Akash Singh

How are GLP-1 receptor agonists changing the management of obesity, type 2 diabetes and cardiometabolic disease? In this lecture from META MEDICON 2026, Dr Akash Singh reviews the expanding role of GLP-1 receptor agonists, with a major focus on semaglutide, from treatment initiation to long-term patient adherence. The session covers obesity, type 2 diabetes, cardiovascular disease, chronic kidney disease and metabolic liver disease. Dr Singh begins by highlighting the growing burden of obesity and diabetes and discusses how contemporary guidelines increasingly prioritize therapies that deliver benefits beyond glucose lowering. He reviews evidence for semaglutide in weight reduction, glycemic control and cardiometabolic risk modification. A major portion of the presentation examines cardiovascular outcome evidence, including studies such as SUSTAIN-6 and SELECT, and discusses the role of semaglutide in patients with established or high-risk atherosclerotic cardiovascular disease. The lecture also reviews emerging real-world data comparing cardiovascular outcomes in patients receiving different incretin-based obesity therapies. The session then explores the role of semaglutide in chronic kidney disease, including data from the FLOW program, with discussion around albuminuria, preservation of kidney function and cardiorenal outcomes. Dr Singh also addresses the evolving evidence for GLP-1 receptor agonists in metabolic dysfunction-associated steatotic liver disease. The final section focuses on the practical barriers to GLP-1 receptor agonist use, including cost, access, gastrointestinal adverse effects, concerns around retinopathy and pancreatitis, patient misconceptions and insufficient clinician familiarity. The talk emphasizes structured patient education, appropriate screening, careful initiation and adherence support. Key topics covered: GLP-1 receptor agonists Semaglutide Obesity pharmacotherapy Type 2 diabetes Cardiometabolic risk reduction Weight-loss outcomes HbA1c reduction SUSTAIN-6 SELECT trial Cardiovascular outcomes Primary and secondary prevention ASCVD risk Chronic kidney disease FLOW trial Albuminuria Kidney function preservation Metabolic liver disease MASLD/MASH GLP-1 therapy initiation Patient adherence Gastrointestinal side effects Retinopathy considerations Pancreatitis precautions Barriers to GLP-1 therapy Patient counselling Speaker: Dr Akash Singh Topic: Transforming Cardiometabolic Practice with GLP-1 Receptor Agonists – From Initiation to Patient Adherence Conference: META MEDICON 2026 – APICON–CCDSICON Gujarat Chapter 2026 Date: 1 August 2026 Venue: Waves Club, Vadodara Hall: CCDSI Hall This video is intended for medical education and professional academic discussion. GLP-1 receptor agonist therapy should be individualized according to indication, comorbidities, contraindications, current evidence and applicable clinical guidelines. #GLP1 #Semaglutide #Obesity #Type2Diabetes #CardiometabolicHealth #ASCVD #CKD #WeightManagement #Diabetology #Cardiology #MedicalEducation #MetaMedicon2026 #IDCM